Pharsight

Drugs that contain Mirabegron

1. Myrbetriq patents expiration

MYRBETRIQ's oppositions filed in EPO
MYRBETRIQ Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6346532 APGDI Amide derivatives or salts thereof
Mar, 2022

(2 years ago)

US7342117 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(5 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6699503 APGDI Hydrogel-forming sustained-release preparation
Sep, 2013

(10 years ago)

US6562375 APGDI Stable pharmaceutical composition for oral use
Aug, 2020

(3 years ago)

US6346532

(Pediatric)

APGDI Amide derivatives or salts thereof
Sep, 2022

(1 year, 6 months ago)

US8835474 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Nov, 2023

(5 months ago)

USRE44872 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Nov, 2023

(5 months ago)

US7982049 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(5 months ago)

US7750029 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Dec, 2023

(4 months ago)

US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(13 days from now)

US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(13 days from now)

US8835474

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
May, 2024

(13 days from now)

USRE44872

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
May, 2024

(13 days from now)

US8772315 APGDI Pharmaceutical composition for treating overactive bladder
Oct, 2028

(4 years from now)

US8772315

(Pediatric)

APGDI Pharmaceutical composition for treating overactive bladder
Apr, 2029

(5 years from now)

US11707451 APGDI Pharmaceutical composition for modified release
Sep, 2029

(5 years from now)

US10842780 APGDI Pharmaceutical composition for modified release
Sep, 2029

(5 years from now)

US10842780

(Pediatric)

APGDI Pharmaceutical composition for modified release
Mar, 2030

(5 years from now)

US11707451

(Pediatric)

APGDI Pharmaceutical composition for modified release
Mar, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-855) Mar 25, 2024
Pediatric Exclusivity(PED) Sep 25, 2024
New Indication(I-777) Apr 27, 2021
New Chemical Entity Exclusivity(NCE) Jun 28, 2017

NCE-1 date: 26 September, 2023

Market Authorisation Date: 28 June, 2012

Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Treatment of overactive bladder with symptoms of urge urinary incontinence, ur...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MYRBETRIQ before it's drug patent expiration?
More Information on Dosage

MYRBETRIQ family patents

Family Patents

2. Myrbetriq Granules patents expiration

MYRBETRIQ GRANULES Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6346532 APGDI Amide derivatives or salts thereof
Mar, 2022

(2 years ago)

US7342117 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(5 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6346532

(Pediatric)

APGDI Amide derivatives or salts thereof
Sep, 2022

(1 year, 6 months ago)

US7982049 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(5 months ago)

US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(13 days from now)

US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(13 days from now)

US10058536 APGDI Pharmaceutical composition containing mirabegron
Mar, 2036

(11 years from now)

US10058536

(Pediatric)

APGDI Pharmaceutical composition containing mirabegron
Oct, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 25, 2024
Pediatric Exclusivity(PED) Sep 25, 2024

Market Authorisation Date: 25 March, 2021

Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

MYRBETRIQ GRANULES family patents

Family Patents